Journal Article

Glucocorticoid tapering and associated outcome in patients with newly diagnosed systemic lupus erythematosus: the real-world GULP prospective observational study

Sebastiani, Gian Domenico, Iannone, Florenzo, Chessa, Elisabetta, Tani, Chiara, Iaccarino, Luca, Franceschini, Franco, Coladonato, Laura, Govoni, Marcello, Cauli, Alberto, Carrara, Greta, Fredi, Micaela, Zanetti, Anna, Conti, Fabrizio, Bellisai, Francesca, Bortoluzzi, Alessandra, Doria, Andrea, Scirè, Carlo Alberto, Spinelli, Francesca Romana, Prevete, Immacolata, Floris, Alberto, Piga, Matteo, Mosca, Marta, D'Alessandro, Roberto

2022

Overview

A subanalysis of the multicentre Early Lupus inception cohort was performed to investigate the real-world Glucocorticoids (GCs) Use in newly diagnosed systemic lupus erythematosus (SLE) Patients (GULP). Patients starting prednisone (PDN) ≥5 mg/day and concomitant hydroxychloroquine or immunosuppressant within 12 months of SLE classification were enrolled. Core set variables were recorded at baseline and every 6 months, including changes in PDN dose, European Consensus Lupus Activity Measurement (ECLAM) and Systemic Lupus International Collaborating Clinics damage index. Regression models analysed predictors of tapering PDN<5 mg/day at any time and outcomes associated with different patterns of GCs tapering. The GULP study included 127 patients with SLE; 73 (57.5%) tapered and maintained PDN <5 mg/day, and 17 (13.4%) discontinued PDN within a 2-year follow-up. Renal involvement (HR: 0.41; p=0.009) and lower C3 serum levels (HR: 1.04; p=0.025) predicted a lack of PDN tapering below 5 mg/day. High ECLAM scores were associated with a greater probability of increasing PDN dose (OR: 1.6; p=0.004), independently of daily intake. Disease relapse rate did not statistically differ (p=0.706) between patients tapering PDN <5 mg/day (42/99, 42.4%) and those tapering PDN without dropping below 5 mg/day (13/28, 46.4%). Every month on PDN <5 mg/day associated with lower damage accrual (IRR: 0.96; p=0.007), whereas never tapering PDN <5 mg/day associated with a higher risk of developing GC-related damage (OR 5.9; p=0.014). Tapering PDN <5 mg/day was achieved and maintained in half of newly diagnosed patients with SLE and may represent a good balance between the need to prevent damage accrual and the risk of disease relapse.

• Publisher: BMJ Publishing Group LTD,BMJ Publishing Group
• Subject: Glucocorticoids - adverse effects / Humans / Immunosuppressive agents / Immunosuppressive Agents - adverse effects / Laboratories / Lupus / Lupus Erythematosus, Systemic - diagnosis / Lupus Erythematosus, Systemic - drug therapy / Observational studies / Patients / Prednisone - adverse effects / Prospective Studies / Regression analysis / Remission (Medicine) / Variables